• Net Element’s reverse merger with EV manufacturer Mullen Technologies expected to close by 4Q2020
• Mullen expects to begin marketing Dragonfly K50, sold in conjunction with JV partner Qiantu Motors from 2Q2021 followed by its own EV SUV in 2022
• Deloitte expects annual EV sales to rise from 2.5mn in 2020 to 31.1mn in 2030, implying 29% CAGR over next ten years
• By 2030, EVs expected to account for 32% of all automobile sales globally, approximately 27% in United States

Net Element (NASDAQ: NETE), a financial technology company which has recently transformed its business model to become a pure-play electric vehicle (“EV”) manufacturer through its merger with privately-held Mullen Technologies Inc., is set to begin marketing its initial vehicle model – the Dragonfly K50 in 2Q2021. The car model, developed in conjunction with China’s Qiantu Motors, will mark Net Element’s initial foray into the North American electric vehicle market—a venture which the company will further reinforce through the launch of its self-manufactured EV SUV, the Mullen MX-5, by the second quarter of 2022.

In an extensive report centered around the battery electric vehicles segment, Deloitte recently forecast that the electric vehicle market is set to reach a tipping point in 2022 – a point of time at which the consultancy expects the cost of ownership for a battery-powered vehicle to be on par with its internal combustion engine-powered counterparts, thereby reducing relative cost differences as a barrier to purchase. With that in mind, it is noteworthy to explore the potential target market size for Net Element as it makes its initial foray into the global EV marketplace (https://ibn.fm/dVlgo).

By 2030, Deloitte anticipates that EV sales could rise from 2.5 million vehicles per annum in 2020 to 31.1 million vehicles per annum—implying a compounded annual growth rate of 29 percent over the next ten years. Moreover, they expect that electric vehicles will secure a market share of 32 percent of total automotive sales by 2030, with battery electric vehicles accounting for 81 percent (25.3 million units) of all new electric vehicles sales and the balance share made up of plug-in hybrid electric vehicles.

However, while electric vehicles are set to grow as a proportion of total automotive sales, their geographic distribution will vary significantly. Deloitte expects EVs to capture a domestic market share of around 48 percent within China by 2030 – almost double that of the United States (27 percent)—with EV sales in Europe accounting for 42 percent of total auto sales in that region.

There are four key factors identified by Deloitte as being key drivers in determining the adoption rate of electric vehicles going forward. First is the shift which is currently being witnessed within consumer sentiment – driving range, a perennial point of contention in the past, has increasingly become less of a concern for potential consumers, with EV driving ranges enjoying a considerable uplift in line with new battery technology breakthroughs. Rather, the primary constraint for future growth may relate to a perceived lack of charging infrastructure, an issue which governments worldwide are seeking to tackle. Germany has recently designated $2.8 billion towards EV charging infrastructure investment while China has recently announced an additional $378 million investment in the technology.

Second is the role of government policy, wherein the widespread adoption of EVs has become a necessary step for governments seeking to achieve their climate-change goals, such as those set by the 2015 Paris Agreement. As a result, a number of governments have offered compelling financial incentives to consumers to make the switch to electric vehicles with other governmental bodies imposing bans, or punitive taxes, on users of older internal-combustion engines to address concerns about toxic air pollution.

The third factor relates to the commercial strategies adopted by various automotive OEMs (original equipment manufacturers). Over the past year, a number of major automotive OEMs have committed to significant upfront investments in developing their EV portfolios, with the likes of Ford announcing that it would invest $11.5 billion on EV models by 2022 while the Volkswagen Group has forecast achieving 1 million EV sales by 2023. More importantly, a greater focus on EVs has led to a greater proliferation of choice available to consumers, with HIS Markit predicting that there will be 130 EV models available to US consumers by 2026, from 43 different automobile manufacturers (https://ibn.fm/esdoB).

Lastly, Deloitte has highlighted the importance of major corporations in helping EV sales transition into the mainstream with the consultancy previously revealing that the sale of new cars to businesses would account for 63 percent of total new car sales across Western Europe by 2021 (https://ibn.fm/qYCbJ).

With traditional company car schemes and car hire operators accounting for a significant proportion of the client wallet for automobile purchases, a greater emphasis on alleviating emissions could result in a significant uplift in EV demand across the corporate spectrum.

Following the completion of the merger between Net Element and Mullen Technologies, the company aims to reach a production threshold of 35,000 vehicles per annum by 2026. With its initial two models already in the works and with the global EV sector set to skyrocket in terms of value over the course of the next decade, Net Element finds itself in the ideal position to capitalize from one of the biggest shifts in consumer behavior the world has ever seen.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

People who suffer from depression usually report that they feel so fatigued that even mundane tasks, such as leaving their beds, are very difficult to manage. According to research, approximately 90% of all the people with major depressive disorder suffer from fatigue. Here are some of the reasons why you may feel fatigued if you suffer from depression.

Sleep Problems

Sleep is essential because it allows the body to replenish its energy supplies and to recover from any damage sustained during the waking hours. If you are depressed, you are likely to have difficulties falling asleep or even staying asleep. This sleep deprivation means that your energy reserves aren’t being replenished as they should, and that accounts for the tiredness you feel.

Other sleep problems, such as obstructive sleep apnea and hypersomnia (constantly feeling sleepy), also increase fatigue.

Your Diet

A meta study done in 2018 found some evidence that a diet which is rich in inflammation-causing foods, such as processed meats, increased one’s likelihood for developing depression and the fatigue associated with those poor dietary choices.

Furthermore, people who are depressed often lack the motivation to be mindful when choosing what to eat, and this increases the odds that they will select foods which aren’t healthy. Such foods will increase the fatigue that the person feels.

Stress

Stress wreaks havoc one’s dopamine and serotonin levels and yet these neurotransmitters play a major role in determining your energy levels and mood. Since chronic stress is usually behind the onset of depression, it is therefore not surprising that when you are depressed, you will feel fatigued all the time.

Research also shows that stress can trigger inflammation in different parts of the body, and that inflammation will sap your energy and leave you feeling fatigued.

Some Medications

Antidepressants help the neurotransmitters in the brain to be more effective at regulating your mood, and therefore alleviate depression. However, some antidepressants have the side effect of making a patient to feel fatigued, and that may explain why you may be feeling tired all the time yet you are taking your medication to combat depression.

There are different coping mechanisms which can help if you are constantly depressed and tired, but perhaps the most important one, which biomedical companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) would be likely to recommend, is for you to talk to an experienced doctor. This professional will assess you before designing an intervention protocol to help you get better. For example, they may prescribe different medication if what you are currently taking is causing you to feel tired all the time.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

By now, you must have heard that hand washing, social distancing, wearing face masks and using a hand sanitizer are valuable tools in the fight against SARS-Cov-2 infection. It now turns out that using a dental mouthwash could also be an additional way to prevent the replication of the coronavirus once it gets into your mouth and throat.

Before you dismiss this suggestion as a wild idea, consider the fact that it was made by none other than the widely respected American Physiological Society. This society was established in 1887 and it brings together all biomedical professionals whose specialty is studying how cells, molecules, tissues and organs function in relation to health and disease. The group publishes 16 peer-reviewed journals whose readership is spread out across the globe.

In their recent evidence review article which appeared in the journal Function, the APS suggests that readily available dental mouthwashes have the capacity to destroy the lipid envelop of different coronaviruses. This destruction would prevent those viruses from replicating in the mouth and throat, thereby averting a likely infection before it takes root.

It should be noted that coronaviruses obtain their lipid envelop from the cells on which they bud (the cells of the host), and this envelop easily succumbs to bio-membrane disruptors.

The authors write that current research shows that the salivary glands and the throat play an important role in the replication and transmission of SARS-Cov-2 viruses. However, while the lipid membrane of these viruses can be easily destroyed, not a lot of research has been done to establish how that can be achieved.

The team suggests that attacking the lipid membrane is easy and even if the coronaviruses mutate, they will still remain vulnerable to the destruction of their lipid envelop.

The APS team also reviewed different ingredients found in approved dental mouthwash products. Those ingredients that could destroy the lipid membrane of the coronaviruses include hydrogen peroxide, ethanol, povidone-iodine, chlorhexidine and so many others.

The review team concludes that several of the mouthwash formulations have so much potential that they deserve to be subjected to clinical studies to evaluate to what extent they would be helpful in destroying the lipid envelop of coronaviruses, and thereby slowing the spread of SARS-Cov-2.

This is an interesting suggestion that could intrigue biomedical sector players like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) who would probably be interested in seeing low-cost solutions of stemming the spread of the ongoing pandemic available to the most vulnerable populations around the world.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

The past decade or so has been pivotal for the auto vehicle industry. The emergence and increasing popularity of automakers like Tesla who only produce electric vehicles (“EVs”) has inspired most automakers to add electric vehicles to their roster of vehicles. This comes at a time when most developed governments are becoming increasingly conscious of pollution and climate change and are taking steps to reduce their carbon footprints.

According to a UK company, not only are EVs energy efficient and produce zero emissions, but they are generally cheaper to run and maintain than diesel or petrol cars. After crunching the numbers, Direct Line found that on average, an electric vehicle is £107 ($139.62) cheaper a year to own than a conventional internal combustion-powered car. The average lifetime running costs for an electric vehicle, including purchase price, is £52,133 ($68,025.75), while an equivalent petrol-powered model will cost you £53,625 ($69,972.58) over its lifetime.

An electric car owner would have to shell out £3,752 ($4,895.80) per year to keep their vehicle running compared to a traditional internal combustion-powered vehicle which costs £3,858 ($5034.11) per year. Thus, an EV owner will save £107 ($139.62) annually, adding up to around £1,070 ($1,396.19) – £1,605 ($2,094.28) over the course of 10-15 years.

This is despite the fact that electric vehicles on average cost £5,000 or 22% more than internal combustion-powered vehicles, even when the Government’s Plug-in Car grant which provides £3,000 subsidies for sub-£50,000 zero-emission cars is considered. Once the initial costs such as purchasing and installing a home charger are covered, Direct Line calculated that an EV owner will spend only £33.50 ($43.71) per week to keep their vehicle running. This is 21% cheaper than the £42.40 ($55.2) per week it would cost to keep a conventional gas-powered vehicle running.

Additionally, the annual tax and maintenance costs (including MOTs and servicing) for electric vehicles are 49% lower than for gas-powered models. It will also cost EV drivers 58% less to refuel (charge) the vehicle. However, due to “current production costs and complexities involved in the calibration of computers used in these cars,” Direct Line says, the insurance costs for EVs are, on average, 25% higher compared to traditional vehicles.

In its research, Direct Line also found that electric cars hold their value better than their gas-powered equivalents, with a year old EV losing only 12% of its value compared to a year old gas-powered vehicle which loses 24% of its value.

This research goes to prove why entities like Net Element (NASDAQ: NETE) believe so strongly that electric vehicles are the future.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Being a man, not being married, and having a low income are some of the factors which new research has shown can increase your risk of dying from COVID-19. This research was conducted by a team at Stockholm University in Sweden and the findings were published in the journal Nature Communications.

The research team combed through the data available at the Swedish National Board for Health and Welfare on the known COVID-19 fatalities in the country. The researchers were specifically interested in the deaths of people aged 20 or older. The statistics studied were from the onset of the pandemic until May 7, 2020.

Information obtained from Statistics Sweden yielded data on the victims’ city of residence, level of education, country of birth, marital status, and age.

The data showed that single people were more likely to die from the novel coronavirus when compared to those who are married. Two possible reasons explain this, according to the researchers.

First, people who are in poor health may be less likely to attract marriage partners, and when the pandemic struck, these people were more likely to succumb to the disease due to their already weakened health status.

Secondly, single people don’t have a protective social system around them, and this makes these individuals more vulnerable in the face of the pandemic. For example, individuals who are surrounded by family are likely to receive better support and care when they are infected by the virus, and this will increase the likelihood of full recovery.

Males were also found to be more susceptible to dying from the virus, and this was attributed to a number of factors, such as lifestyle and biology. For instance, men are more risk-taking when compared to women. This potential for risky behavior increases the chance that men will be exposed to, and eventually succumb to COVID-19. Men also generally take longer to admit that something is amiss, and this gives the infection an opportunity to progress before the person seeks medical help.

People with low education and low incomes also seem to have high COVID-19 mortality outcomes. When one’s income is low, the person is less likely to put their health at the top of their list of priorities (they must keep working to feed their families, for example). These lifestyle factors make low income and low education a strong factor in coronavirus mortality.

In many respects, this research doesn’t depart a great deal from other studies which have looked at the factors behind mortality due to different health conditions. For this reason, entities like DarioHealth Corp. (NASDAQ: DRIO) are unlikely to find any new information from the Swedish research with the exception of its focus on COVID-19.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• 180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions.
• Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with first results expected in 2021
• The company is to be acquired by a SPAC (NASDAQ: KBLM) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF

Pioneering biotech company, 180 Life Sciences Corp. is bringing hope to sufferers of Dupuytren’s Disease and other inflammatory conditions caused by an impaired immune system. Currently, the company has three major programs underway focused on therapies for separate areas of inflammation. These programs are headed by a team of renowned scientists who have already developed blockbuster drugs, discovered an entire drug class and made ground-breaking discoveries in their fields. The programs are exploring therapies expected to bring relief to those afflicted by a variety of TNF conditions, including ‘frozen shoulder,’ Dupuytren disease, postoperative cognitive dysfunction (“POCD”), and non-alcoholic fatty liver disease (“NAFLD”).

TNF is one of those good things, a surfeit of which, can turn out bad. A protein released by white blood cells to mobilize the body’s defenses, i.e. the immune system, TNF plays an essential role in fighting off diseases of many kinds. TNF triggers inflammation to create an environment conducive to healing infected or damaged tissue. Typically, this state of affairs continues just long enough to repair damage to the cells. Regular or acute inflammation lasts for a short time, going away within hours or days. But sometimes, TNF sets the inflammatory process in motion when there’s no threat, a situation that can persist for a lengthy period, leading to what is known as chronic inflammation. Chronic inflammation opens a Pandora box of ailments. Conditions linked to chronic inflammation include Alzheimer’s disease, asthma, cancer, diabetes, heart disease, and a number of others that 180 Life Sciences Corp. is currently conducting research on.

The Company’s Three Research Programs Are: 

The fibrosis and anti-TNF program, based at the Kennedy Institute, University of Oxford, U.K.

The program is addressing four critical areas of inflammation:

• Dupuytren disease, a debilitating condition that causes the fingers to irreversibly curl toward the palm. Dupuytren disease affects some 15 million Americans over the age of 35, about 5 percent of the U.S. population, according to a 2014 CDC study (https://nnw.fm/EkAff). Top line data from Phase 2b/3 trials are expected by Q4 2021.
• Frozen shoulder is a musculoskeletal impairment that makes it difficult or impossible to move the shoulders (https://nnw.fm/z1sYI). Phase 2b trials are set to begin Q3 2021.
• POCD affects patients, particularly older ones, after surgical operations. In one study, roughly 12 percent of patients over age 60 had postoperative cognitive dysfunction, three months after surgery (https://nnw.fm/sd9OI). Phase 2 trials in POCD are anticipated to commence in Q4 2021.
• Nonalcoholic steatohepatitis (“NASH”) is a type of non-alcoholic fatty liver disease, aggravated by hepatitis (https://nnw.fm/9fn00). Preclinical studies in liver fibrosis and NASH are set to begin in late 2020.

 Synthetic CBD Analogs (“SCAs”) – Preclinical – based at the Hebrew University of Jerusalem

The SCA program is based at the Hebrew University of Jerusalem, in Israel, with additional research and trials at the Kennedy Institute, at the University of Oxford.

180 Life Sciences is aiming to develop SCAs that are safe and non-psychoactive and formulated to improve efficacy, as an alternative to naturally occurring cannabidiol (“CBD”). The program is led by a team that includes Professor Raphael Mechoulam, the first to ‘discover’ tetrahydrocannabinol (“THC”). 180 Life Sciences is aiming to create a compound that is 99.5% pure CBD, which will drastically improve medical prescriptive precision. The program is also exploring a drug delivery platform—ProNanoLipospheres (“PNL”)—to improve bioavailability.

The α7nAChR program, based at Stanford University in the US.

The α7nAChR program is searching for an effective therapy to treat ulcerative colitis in ex-smokers. α7nAChR is a nicotine receptor and is a central factor in the body’s method of controlling inflammation.

180 Life Sciences Corp. is to be acquired by KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (“SPAC”), after which the combined entity will be listed on Nasdaq under the ticker symbol: ATNF.

For more information, visit the companies’ websites at www.180LifeSciences.com and www.KBLMerger.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://nnw.fm/180

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• SGTM awarded contract for tree services in Lake County, Florida through subsidiary Central Florida Arborcare
• SGTM subsidiary Mulch Manufacturing recently awarded two additional packaging contracts
• Subsidiary ArborPro of Mississippi Inc. awarded contract for Hurricane Laura recovery efforts
• Q2 results include $12.3 million revenue and $3.4 million gross profit

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally-beneficial solutions for tree and storm waste disposal, recently announced that Central Florida Arborcare, its wholly-owned subsidiary, was awarded a one-year contract to supply tree trimming and related services to the county, renewable for an additional four times over a one-year period. Along with tree services, SGTM provides debris hauling and waste removal as part of its overall operations that transform organic waste into environmentally-friendly products such as mulch and playground surfacing material.

“Getting awarded this contract is allowing us to stay on point with our growth, building relationships with municipalities and governments,” said SGTM CEO and Director Tony Raynor (https://nnw.fm/IoXrd). “We are very fortunate to be an essential business that has proven to stand strong through these economically hard times.”

Despite the economic hardships currently being experienced by businesses across the country, SGTM has grown. The new contract comes shortly after subsidiary Mulch Manufacturing Inc. was awarded a 2021 mulch packaging contract renewal from Menards Inc., the third-largest home improvement chain in the U.S. with 350 stores in operation across 15 states. Also in the pipeline for Mulch Manufacturing is another contract with Old Castle Lawn & Garden to supply large home improvement chains in the Midwest. ‘

SGTM takes its role as a caretaker of the environment seriously by providing remediation efforts in the wake of hurricanes and other natural disasters such as Hurricane Laura. Through its strategic partner, ArborPro of Mississippi Inc., SGTM contributed to recovery efforts in Louisiana by providing services that diverted damaged trees and other vegetation from landfills. The busy hurricane season is expected to contribute significantly to the company’s bottom line this quarter, building upon already impressive Q2 results that included over $12.3 million in revenue and $3.4 million in gross profit (http://nnw.fm/iiGDM).

SGTM plans to expand operations through a combination of organic growth, national partnerships and strategic acquisitions. The company’s strong commitment to environmental sustainability was a primary factor behind the recent name and ticker change from National Storm Recovery Inc. (OTC: NSRI) to Sustainable Green Team, Ltd. (OTC: SGTM). Along with driving forward its mission, the company also aims to maximize value to shareholders seeking ethical investment opportunities in businesses with significant growth potential that can withstand increasingly challenging economic conditions.

To learn more about Sustainable Green Team Ltd., view the investor presentation at http://nnw.fm/UpXmd.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Days characterized by extreme air pollution and extreme high heat are increasing in frequency in different parts of the world. For example, New Delhi in India experienced a week of the worst ever air pollution that had ever been recorded anywhere in human history in November last year. Shortly before that extreme event, Western Europe saw two heatwaves that left at least 1,500 people dead. These developments prompted a team at Texas A&M University to investigate what would happen if extreme heat coincided with extreme air pollution.

The researchers used a computer model to analyze the likelihood of extreme heat and extreme air pollution coinciding in South Asia. This particular computer model used data on the trends of greenhouse gas emissions, population growth, effects of terrain, weather and oceans on air pollution.

Based on their findings, the researchers predict that there is going to be a massive increase in the number of days that feature both extreme heat and extreme air pollution by 2050. In fact, a 175% increase, amounting to 78 days of extreme air pollution and extreme heat, is predicted.

The researchers selected South Asia because this part of the world is a red zone on matters of climate change, and its population is expected to reach 2 billion in 2050 from the current 1.5 billion.

Furthermore, the computer model revealed to the research team that the land area affected by the double whammy of extreme air pollution coinciding with extreme high heat would balloon tenfold from the year 2000 to 2050. This land area is expected to host 25% of all the people in South Asia, up from the current 2%. Why should these extreme weather events concern us?

It is a known fact that extreme air pollution and extreme high heat have adverse effects on human health. Experts say biomed companies like Processa Pharmaceuticals Inc. (NASDAQ: PCSA) are likely to agree that cases of heat stroke and heat exhaustion increase each time ambient temperature rises to heat wave levels. Additionally, chronic health conditions, such as heart disease, worsen under such conditions.

In the same vein, extreme air pollution plays a significant role in the onset or exacerbation of asthma, pregnancy complications, heart disease as well as other serious health conditions.

The researchers therefore fear that people with these health conditions could be severely affected when a combination of extreme heat and extreme air pollution coincide as it has been known for long that exposure to additional environmental stressors worsens an individual’s susceptibility to the adverse effects of each of the existing stressors.

The team suggests that additional studies need to be done to establish who exactly is at risk from extreme weather events. And collective action needs to be taken to avert the worse-case scenario predicted by the computer model. Ramping up green energy solutions is one way to reduce CO2 emissions, for example.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Predictive Oncology’s CEO Carl Schwartz published open letter to company’s shareholders
• Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward
• CEO also revealed that company’s revenue trends have stabilized and are now on upward trend with cash burn beginning to decline
• Company also revealed its ability to access over $10 million in undrawn equity lines of credit

Carl Schwartz, the CEO of Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has recently published a letter to the company’s shareholders elaborating on the company’s latest achievements as well as their prospects going forward (https://ibn.fm/L1mA8).

Within his letter, Schwartz addressed the latest developments within each of the company’s business verticals and stressed that in spite of the tumultuous global economy, Predictive Oncology was witnessing both stable and rising revenues along with declining levels of cash burns. Schwartz also detailed that the company’s balance sheet was still quite resilient with access to over $10 million in equity capital able to be drawn down from their existing lines of credit.

The letter also elaborated on the company’s various operational divisions, commencing with its Skyline Medical division. Skyline Medical is charged with the manufacture and sale of POAI’s groundbreaking, FDA-cleared STREAMWAY System – providing medical facilities with a direct-to-drain fluid disposal system intended to automate the collection, measurement and disposal of waste fluids during medical procedures. POAI revealed that the division was now self-supporting from a cash standpoint, with sales of disposables used on Streamway machines more than covering the business’ operating expenses. Separately, the company explained that the continued sale of new Streamway devices would also add to the future potential revenues which the company could derive from the sale of disposables.

Schwartz also touched upon the company’s Helomics division, which seeks to assist pharmaceutical, diagnostic and biotech industries develop predictive models of how tumors could respond to drugs. Helomics recently launched a restructured clinical test offering to clinicians for ovarian cancer, which has been very well received by oncologists. The company expects that this new test, coupled with Helomic’s existing product range, will be revenue generating by year end and should be able to cover the bulk of the division’s operating expenses going forward.

Elsewhere, Predictive Oncology also provided an update on subsidiary TumorGenesis, which specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians identify which cancer cells bind to specific biomarkers. TumorGenesis will be introducing its Ovarian Cell Line Media at the upcoming BIO-Europe Conference, which will allow researchers to isolate and successfully culture ovarian cancer cells that have not previously been cultured. Separately, the division is also in the process of registering with the US government as a contractor for developmental work in cancer cell capture and screening of compounds for the prevention and treatment of cancer.

Finally, Schwartz discussed the ongoing progress at Soluble Biotech, a subsidiary which seeks to provide optimized FDA-approved formulations for vaccines, antibodies and other protein therapeutics in a faster and lower cost basis to its customers. Having already secured a sizable contract, POAI’s management have expressed their confidence in the business generating revenues by the end of 2020.

With a number of ongoing positive developments taking place across Predictive Oncology’s various businesses, the company’s CEO has reaffirmed his positive stance on POAI’s corporate prospects, expressing his firm belief in the fourth quarter’s being “eventful”.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

The World Economic Forum estimates that robotics and automation can avert about 10,000 injuries within the metals and mining industries in just a decade, and that autonomous hauling could improve productivity by at least 15-30%. These figures are realistic and they highlight why autonomous mining should be pursued with urgency. Here are some of the things that need to happen for autonomous mining to become a widespread reality.

Establish the Foundation

For fully autonomous mining to exist, a core IT architecture needs to be set up so that every piece of mining equipment can communicate seamlessly with the different systems at the site. For example, it would be disastrous if a Hitachi excavator on site cannot communicate with a Caterpillar truck hauling materials off the site.

Cyber-security also needs to be carefully thought about and enhanced to avert the catastrophes which can result if hackers ever get control of the autonomous mining operations.

Data Readiness is a Must

Lots of data from numerous sources is needed to avail the raw material which analytics tools and artificial intelligence systems need to support all the decision-making processes during mining. Mining companies therefore have to prepare to capture as well as manage constantly growing volumes of data while at the same time making sure that all that data can be trusted and relied upon as the autonomous systems are making decisions.

If data readiness isn’t achieved, automation would be hard to implement, or it would be severely limited in scope.

Manage the Change

If a mining enterprise is to succeed at fully automating its mining operations, companies like Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) would need to invest heavily in reskilling and retraining their employees so that they can be ready to work in the new autonomous setting. While some people may think that automation leads to job cuts, the truth is that many more jobs are created than those which are lost. The only difference is that the new jobs available aren’t along the same lines as those which previously existed.

For example, undergoing training as a mining truck driver isn’t wise when automation is looming. Rather, getting skilled as a data analytics specialist or data scientist, or even as an autonomous truck maintenance technician is a lot more forward-looking.

As the years roll by, there is likely to be a shift towards even greater environmental and human safety. This focus will compel mining entities to make gradual shifts to full automation, and as that momentum builds, autonomous mining will become the norm.

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

According to the work of Rutgers researchers published in the journal Epigenetics, kids who are born to diabetic mothers are prone to aging faster biologically and they may also be more susceptible to high blood pressure and obesity later in life.

The study analyzed more than 1,000 Chinese children born by mothers who had diabetes during pregnancy in order to understand their biological aging process. Of interest to the research team was the in utero exposure of the kids to diabetes and how that affected DNA methylation. Epigenetic methylation looks at how exposure to different conditions and environments accelerates or slows down the aging process at a cellular level.

Scientists can determine whether your DNA methylation matches with your chronological age or makes you biologically older than you actually are in terms of the years one has spent on earth. Individuals with a higher DNA methylation have been linked to a higher propensity to develop high blood pressure as well as other poor health outcomes later in life.

For this particular study, the team of researchers focused on 1,156 kids in Tianjin, China. The kids were aged between three and ten years old. When the epigenetic age of these kids was measured, it was found that all the children who were born to mothers that had diabetes while pregnant were biologically older than their chronological age.

This higher epigenetic age relative to the chronological age of the kids puts those children at a higher risk of having a higher BMI (body-mass index, a measure of whether someone is overweight, obese or of normal weight for their height). The kids were also found to be prone to having a higher percentage of body fat and a larger upper arm circumference.

Stephanie Shiau, the lead author of the study who also works as an instructor at the Rutgers School of Public Health, says that the findings show that gestational diabetes could have long-term adverse effects on the cardiometabolic health markers of the individuals.

This research makes a strong case for additional longitudinal studies (research which follows up the study subjects several years after the initial study) to get additional data about the link between one’s epigenetic age and the future onset of metabolic diseases in adulthood.

According to the National Institutes of Health (“NIH”), about 2-10% of all pregnancies in the U.S. are affected by gestational diabetes. This means that millions of kids are at high risk of developing the health problems linked to their higher epigenetic age.

DarioHealth (NASDAQ: DRIO), a global digital therapeutics company serving its users with dynamic mobile health solutions, is a company operating within the diabetes management market to keep an eye on.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• CNS Pharmaceuticals is a pre-clinical-stage developer of novel brain cancer-fighting drugs, including its lead candidate Berubicin
• The company is working to build on promising results from a 2006 Phase I trial, which provided 44 percent of its limited patient pool with clinically significant improvement in disease stability and one patient with a durable complete response (no evidence of any tumor remaining) for over 14 years
• CNS Pharmaceuticals expects to launch a pivotal Phase II trial of Berubicin at the beginning of next year and has been assembling a team of partner companies help with the trial
• CNS recently announced that the partner contracted to manufacture the Active Pharmaceutical Ingredient (API) for Berubicin has received a Certificate of Analysis necessary for the drug substance to be used in the clinical trial
• The company is also preparing in collaboration with its sub licensed partner, WPD Pharmaceuticals, for the first Phase I pediatric trial of Berubicin
• CNS is continuing the pre-clinical development of the company’s second promising cancer-fighting drug candidate, WP1244

Houston, Texas-based biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to achieve milestones in its drive to defeat glioblastoma multiforme (“GBM”), a relentless type of brain tumor known for very rapid progression and very short survival periods in nearly all patients once they’ve been diagnosed.

“If you get glioblastoma, the sad fact is you’re going to die from that disease,” CNS Pharmaceuticals CEO John Climaco told attendees at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit in September during a discussion about the aggressive brain tumors and the company’s investment potential as it advances tumor-fighting drug candidates (https://ibn.fm/t13u4). “We believe that [our drug candidate] Berubicin could potentially be a game-changer,” Climaco continued.

CNS Pharmaceuticals is in the process of developing the testing infrastructure for its its lead novel drug candidate, an anthracycline called Berubicin. The company announced at the beginning of this month that a partner company contracted to manufacture Berubicin active pharma ingredient (API) received a Certificate of Analysis, clearing it for use in the production of the Berubicin drug product in preparation for use in the clinical trial (https://ibn.fm/N2AMO).

Berubicin has shown the potential to stand out from other tumor-killing anthracyclines because it has the ability to cross the human body’s Blood-Brain Barrier (“BBB”) and sequester itself preferentially in tumor tissue, the company’s website states (https://ibn.fm/F8SNr).

The blood-brain barrier is a wall of specialized endothelial cells that separate the blood circulatory system from the brain and kick out recognized toxins such as anthracyclines before they can affect the body’s central nervous system. “That’s why anthracyclines kill glioblastoma cells in test tubes but don’t affect glioblastoma tumors when given to people,” the website states.

In a limited Phase I trial conducted in 2006, Berubicin showed evidence of prompting improved survival in a patient population that has a median survival rate of only 14.6 months from the date of the disease’s diagnosis, and one of the trial’s patients remains cancer-free as of the last assessment on Feb. 20 of this year, approximately 14 years later, Climaco said.

Tumors are generally first removed surgically to the extent possible, but then tend to recur.

The pharmaceutical temozolomide has been shown useful as a first-line response in temporarily extending the lifespan of fewer than 40 percent of GBM patients with a specific genetic variation, but even nearly all of those patients develop resistance to temozolomide within about a year’s time and CNS hopes to present Berubicin as a second-line therapy.

The contracts with drug manufacturers Pii and BSP will provide drug product for CNS’s Phase II clinical trial as well as two trials in Poland to be conducted by sub licensee partner, WPD Pharmaceuticals, including a Phase 2 adult trial and a first-ever Phase 1 pediatric trial, both of which are expected to launch during Q1 of 2021. The company recently announced an agreement with medical imaging company Image Analysis Group (“IAG”) to evaluate the upcoming clinical trial imaging results in real time using AI-driven technology (https://ibn.fm/TlKhu).

CNS Pharmaceuticals is also conducting pre-clinical development on a drug candidate known as WP1244 that has been shown in preclinical studies to have a DNA-binding agent 500 times more potent than chemotherapy drug daunorubicin in stopping tumor cell expansion.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Months into the coronavirus pandemic, the state-legal cannabis industry is still going strong. Although the pandemic forced many industries to shut down, resulting in the loss of millions of jobs, the cannabis industry has fared quite well despite the economic crisis. Most states have seen increased cannabis sales month over month, with some even calling the industry ‘recession-proof’.

One such state is Illinois, which has seen record-breaking marijuana sales for the fifth time in a row. In September, consumers purchased more than 1.4 million marijuana products worth nearly $67 million, with almost $18 million of those sales coming from out-of-state visitors, according to the state Department of Financial and Professional Regulation. This is a slight increase compared to the 1.3 million marijuana products sold for a total of nearly $64 million in August.

In July, Illinois reported nearly $61 million in adult-use cannabis sales, beating out by a wide margin the $44,749,787 worth of cannabis sold in June.

Although the data from September doesn’t include data about purchases made through the state’s medical cannabis program, it seems to support the notion that the cannabis industry is recession-proof.

Like most states that have legalized cannabis, Illinois declared the cannabis industry essential, allowing businesses to keep operating amidst the lockdown orders.

State officials say that although the month over month increase in sales is positive economic news, they are more interested in directing cannabis tax revenue towards restorative justice measures. Most states that allow cannabis have provisions that allocate cannabis tax revenue to programs that reinvest in communities most affected by the decades’ long war on drugs and Illinois is no different.

Illinois has brought in around $52 million in cannabis tax revenue in the first six months since retail sales began in January. Back in May, the state announced that $31 million in restorative justice grants sourced from cannabis sales tax would be available. Under a Restore, Reinvest, and Renew (R3) program established by the legalization bill, the funds would be used to provide grant opportunities for “communities impacted by economic disinvestment, violence and the severe and multilayered harm caused by the war on drugs.”

Later in July, the state announced that 25% of cannabis tax revenue would go toward a social equity program. “We were not doing this to make as much money as we could, “says Toi Hutchinsons, senior cannabis advisor to Gov. J.B Pritzker. “We were actually doing this for the people.”

Many cannabis industry players like The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) believe that legalizing and regulating the industry would bring untold economic benefits, and the figures from Illinois prove this to be the case.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.